XLRN - アクセルロン・ファ―マ (Acceleron Pharma Inc.)

XLRNのニュース

   The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data  2020/10/13 12:20:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc (NASDAQ: XLRN ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) argenx SE – ADR (NASDAQ: ARGX ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kronos Bio Inc (NASDAQ: KRON ) (went public Friday) Kura Oncology Inc (NASDAQ: KURA ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lantern Pharma Inc.
   The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut  2020/10/01 12:18:26 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Annexon Inc (NASDAQ: ANNX ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) CTI BioPharma Corp (NASDAQ: CTIC ) I-Mab ADR (NASDAQ: IMAB ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) (the blank check company announced a business combination with oncology-focused Vincera Pharma) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PMV Pharmaceuticals Inc (NASDAQ: PMVP ) PPD Inc (NASDAQ: PPD ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 30) Abeona Therapeutics Inc (NASDAQ: ABEO ) Alector Inc (NASDAQ: ALEC ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Neos Therapeutics Inc (NASDAQ: NEOS ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) Pandion Therapeutics Inc (NASDAQ: PAND ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Theravance Biopharma Inc (NASDAQ: TBPH ) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Amag Reportedly Pursued By Apollo's Covis Pharma AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) shares surged higher after a Bloomberg report said Apollo Management's Covis Pharma unit is in advanced talks to buy Amag.
   The Daily Biotech Pulse: Eton Snags Second FDA Nod For Month, Vaccine Updates from Moderna, CureVac  2020/09/30 11:45:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc (NASDAQ: XLRN ) (announced Health Canada approval of luspatercept for RBC transfusion-dependent anemia associated with beta-thalassemia) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Adial Pharmaceuticals Inc (NASDAQ: ADIL )(announced EUA for antibody test for COVID-19) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO )(announced dosing of first patient in ulcerative colitis study) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc.
   Hormone Refractory Prostate Cancer (HRPCA) Market Analysis, Top Companies, Growth rate and Forecasts to 2027 | AbbVie, Acceleron Pharma, AB Science SA, AstraZeneca Plc., Astellas Pharma, Boston Biomedical  2020/09/30 08:19:15 OpenPR
Global Hormone Refractory Prostate Cancer (HRPCA) Market Report The ‘Global Hormone Refractory Prostate Cancer (HRPCA) Market Insights, Forecast to 2027’ offers a comprehensive evaluation of the Hormone Refractory Prostate Cancer (HRPCA) market on the global scale and sheds light on the
   Acceleron to Host Webcast Outlining the Design of Its Registrational Phase 3 STELLAR Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) on October 2, 2020  2020/09/17 20:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast for investors and analysts on Friday, October 2, 2020 at 8:00 a.m. EDT to discuss the design of its first registrational Phase 3 STELLAR trial of sotatercept in patients with pulmonary arterial hypertensio
   Acceleron Reports Second Quarter 2020 Operating and Financial Results  2020/08/06 20:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020. “Acceleron had another productive quarter marked by additional regulatory approvals of REBLOZYL in the U.S. and E.U., strong product uptake resulting in s
   Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales  2020/08/06 11:10:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) in the United States as reported by its global collaborator, Bristol Myers Squibb, were approximately $55.0 million for the second quarter ended June 30, 2020. Acceleron expects to report royalty revenue
   Acceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020  2020/07/27 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 6, 2020 at 5:00 p.m. EDT to discuss its second quarter 2020 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company’s website at acceleronpharma.com. Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (inte
   The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs  2020/07/24 07:15:00 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Acceleron Pharma Inc …
   Acceleron Announces Pricing of Public Offering of Common Stock  2020/06/30 22:48:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has priced an underwritten public offering of 4,864,864 shares of common stock at a price to the public of $92.50 per share for gross proceeds of $450.0 million. In connection with this offering, Acceleron has granted the underwriters a 30-
   Acceleron Reports Second Quarter 2020 Operating and Financial Results  2020/08/06 20:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020. “Acceleron had another productive quarter marked by additional regulatory approvals of REBLOZYL in the U.S. and E.U., strong product uptake resulting in s
   Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales  2020/08/06 11:10:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) in the United States as reported by its global collaborator, Bristol Myers Squibb, were approximately $55.0 million for the second quarter ended June 30, 2020. Acceleron expects to report royalty revenue
   Acceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020  2020/07/27 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 6, 2020 at 5:00 p.m. EDT to discuss its second quarter 2020 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company’s website at acceleronpharma.com. Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (inte
   The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs  2020/07/24 07:15:00 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Acceleron Pharma Inc …
   Acceleron Announces Pricing of Public Offering of Common Stock  2020/06/30 22:48:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has priced an underwritten public offering of 4,864,864 shares of common stock at a price to the public of $92.50 per share for gross proceeds of $450.0 million. In connection with this offering, Acceleron has granted the underwriters a 30-

calendar